Assessing the Potential of C-Reactive Protein Testing to Reduce Antibiotic Dispensation for Respiratory Tract Infections by Community Pharmacists in Nigeria: A Cluster Randomised Controlled Trial
Not Applicable
Completed
- Conditions
- Antibiotic use for respiratory tract infections
- Registration Number
- PACTR202111611256940
- Lead Sponsor
- Augustine Onwunduba
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
To be included, a community pharmacy must be registered with the Pharmacists Council of Nigeria (PCN) and have at least one pharmacist, who is registered with PCN, on duty always.
Exclusion Criteria
Prospective community pharmacies will be excluded if their managements do not consent to their participating or if their community pharmacists already use a diagnostic technique to inform antibiotic dispensation to patients with RTI symptoms.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the role of C-Reactive Protein as a biomarker for antibiotic stewardship in Nigerian community pharmacies?
How does C-Reactive Protein testing compare to standard-of-care diagnostic methods for respiratory tract infections in low-resource settings?
What molecular mechanisms underlie C-Reactive Protein's utility in predicting bacterial versus viral infections in respiratory disease?
Are there alternative biomarkers to CRP that could improve antibiotic prescribing accuracy in community pharmacy settings?
What adverse events are associated with CRP-guided antibiotic dispensing by community pharmacists in sub-Saharan Africa?